Business Context and Reporting Period
This Form 8-K filing by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) reports on events occurring on June 6, 2018. The document details the results of the Company's Annual Meeting of Stockholders held on that date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Directors
- Harrison M. Bains, Jr. was elected to the Board of Directors until the 2021 Annual Meeting.
- Votes For: 5,782,274
- Votes Withheld: 1,693,373
- Broker Non-Votes: 15,901,958
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- Stockholders ratified the selection of Ernst & Young LLP for the year ending December 31, 2018.
- Votes For: 23,083,086
- Votes Against: 196,120
- Votes Abstain: 98,399
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote.
Investor Verification Checklist
- Verify the significant number of Broker Non-Votes (15,901,958) relative to votes cast for the director election.
- Confirm the tenure of the newly elected director, Harrison M. Bains, Jr., extending to the 2021 Annual Meeting.
- Review the Proxy Statement filed on April 26, 2018, for detailed descriptions of the proposals referenced in this filing.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.